JP2022544785A5 - - Google Patents
Info
- Publication number
- JP2022544785A5 JP2022544785A5 JP2022509060A JP2022509060A JP2022544785A5 JP 2022544785 A5 JP2022544785 A5 JP 2022544785A5 JP 2022509060 A JP2022509060 A JP 2022509060A JP 2022509060 A JP2022509060 A JP 2022509060A JP 2022544785 A5 JP2022544785 A5 JP 2022544785A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- modified
- sequence
- polypeptide
- polypeptide according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025203501A JP2026032136A (ja) | 2019-08-13 | 2025-11-26 | 改変インターロイキン２受容体ベータアゴニスト |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962886148P | 2019-08-13 | 2019-08-13 | |
| US62/886,148 | 2019-08-13 | ||
| PCT/US2020/046244 WO2021030633A1 (en) | 2019-08-13 | 2020-08-13 | Engineered interleukin-2 receptor beta agonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025203501A Division JP2026032136A (ja) | 2019-08-13 | 2025-11-26 | 改変インターロイキン２受容体ベータアゴニスト |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022544785A JP2022544785A (ja) | 2022-10-21 |
| JP2022544785A5 true JP2022544785A5 (https=) | 2023-08-22 |
| JP7783164B2 JP7783164B2 (ja) | 2025-12-09 |
Family
ID=72243240
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022509060A Active JP7783164B2 (ja) | 2019-08-13 | 2020-08-13 | 改変インターロイキン２受容体ベータアゴニスト |
| JP2025203501A Pending JP2026032136A (ja) | 2019-08-13 | 2025-11-26 | 改変インターロイキン２受容体ベータアゴニスト |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025203501A Pending JP2026032136A (ja) | 2019-08-13 | 2025-11-26 | 改変インターロイキン２受容体ベータアゴニスト |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230002466A1 (https=) |
| EP (1) | EP4013774A1 (https=) |
| JP (2) | JP7783164B2 (https=) |
| KR (1) | KR20220044534A (https=) |
| CN (1) | CN114787182A (https=) |
| AU (1) | AU2020329290A1 (https=) |
| CA (1) | CA3147677A1 (https=) |
| WO (1) | WO2021030633A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11633488B2 (en) | 2020-01-10 | 2023-04-25 | Bright Peak Therapeutics Ag | Modified IL-2 polypeptides and uses thereof |
| CA3169095A1 (en) * | 2020-03-05 | 2021-09-10 | Kenan Christopher GARCIA | Designed il-2 variants |
| WO2022115865A2 (en) | 2020-11-25 | 2022-06-02 | Xilio Development, Inc. | Tumor-specific cleavable linkers |
| IL304365B2 (en) | 2021-03-31 | 2025-04-01 | Hanmi Pharmaceutical Co Ltd | A novel conjugate of an IL2 immunostimulatory analog and method of preparation thereof |
| CN113603791A (zh) * | 2021-08-11 | 2021-11-05 | 厦门目青股权投资合伙企业(有限合伙) | 一种融合蛋白及其应用 |
| CN119731199A (zh) * | 2022-05-10 | 2025-03-28 | 艾佩斯瑞生物制药公司 | 工程化的白细胞介素-2受体β降低结合的激动剂 |
| WO2025010341A2 (en) * | 2023-07-05 | 2025-01-09 | The Trustees Of Dartmouth College | Cytokine hybrid proteins and methods related thereto |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4604377A (en) | 1984-03-28 | 1986-08-05 | Cetus Corporation | Pharmaceutical compositions of microbially produced interleukin-2 |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| ATE332368T1 (de) | 1997-01-21 | 2006-07-15 | Gen Hospital Corp | Selektion von proteinen mittels rns-protein fusionen |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| PL209392B1 (pl) | 1999-01-15 | 2011-08-31 | Genentech Inc | Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała |
| ES2248127T3 (es) | 1999-10-04 | 2006-03-16 | Medicago Inc. | Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno. |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| US7083784B2 (en) | 2000-12-12 | 2006-08-01 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
| WO2003059934A2 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
| HUE027902T2 (en) | 2004-02-09 | 2016-11-28 | Human Genome Sciences Inc Corp Service Company | Albumin fusion proteins |
| AU2005304624B2 (en) | 2004-11-12 | 2010-10-07 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| AU2007271398B2 (en) * | 2006-07-06 | 2013-06-20 | Merck Patent Gmbh | Compositions and methods for enhancing the efficacy of IL-2 mediated immune responses |
| CA2860170C (en) | 2010-12-22 | 2022-06-14 | The Board Of Trustees Of The Leland Stanford Junior University | Superagonists and antagonists of interleukin-2 |
| SG192673A1 (en) * | 2011-02-10 | 2013-09-30 | Roche Glycart Ag | Mutant interleukin-2 polypeptides |
| WO2012119093A1 (en) | 2011-03-03 | 2012-09-07 | Board Of Trustees Of The Leland Stanford Junior University | Superagonists and antagonists of interleukin-2 |
| CN109535259A (zh) * | 2012-12-05 | 2019-03-29 | 生控基因疫苗股份有限公司 | 用作诱发抗原特异性t细胞反应的免疫原性增强剂的融合蛋白 |
| WO2015164815A1 (en) * | 2014-04-24 | 2015-10-29 | The Board Of Trustees Of The Leland Stanford Junior University | Superagonists, partial agonists and antagonists of interleukin-2 |
| CN107207603A (zh) * | 2015-02-03 | 2017-09-26 | 吉安特科技股份有限公司 | 趋化因子‑免疫球蛋白融合多肽，其组合物、制备方法以及用途 |
| US11655452B2 (en) * | 2015-06-25 | 2023-05-23 | Icell Gene Therapeutics Inc. | Chimeric antigen receptors (CARs), compositions and methods of use thereof |
| MX2021000801A (es) * | 2018-07-24 | 2021-04-12 | BioNTech SE | Agonistas de il2. |
-
2020
- 2020-08-13 KR KR1020227007082A patent/KR20220044534A/ko active Pending
- 2020-08-13 CA CA3147677A patent/CA3147677A1/en active Pending
- 2020-08-13 EP EP20761980.0A patent/EP4013774A1/en active Pending
- 2020-08-13 JP JP2022509060A patent/JP7783164B2/ja active Active
- 2020-08-13 WO PCT/US2020/046244 patent/WO2021030633A1/en not_active Ceased
- 2020-08-13 AU AU2020329290A patent/AU2020329290A1/en active Pending
- 2020-08-13 US US17/634,688 patent/US20230002466A1/en active Pending
- 2020-08-13 CN CN202080066791.1A patent/CN114787182A/zh active Pending
-
2025
- 2025-11-26 JP JP2025203501A patent/JP2026032136A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022544785A5 (https=) | ||
| Nuñez-Prado et al. | The coming of age of engineered multivalent antibodies | |
| CN107922486B (zh) | 异源二聚体多特异性抗体形式 | |
| Morris et al. | Advances in interleukin 2 receptor targeted treatment | |
| Stork et al. | A novel tri-functional antibody fusion protein with improved pharmacokinetic properties generated by fusing a bispecific single-chain diabody with an albumin-binding domain from streptococcal protein G | |
| AU2018280683B2 (en) | Hetero-dimeric multi-specific antibody format targeting at least CD3 and HSA | |
| Kontermann et al. | Bispecific antibodies | |
| JP2024099850A5 (https=) | ||
| JP2023123649A5 (https=) | ||
| JP2022544771A5 (https=) | ||
| JP2022512043A5 (https=) | ||
| JP2023504914A5 (https=) | ||
| JP2013529070A5 (https=) | ||
| JP2021522162A5 (https=) | ||
| CN111527109A (zh) | 以抗体Fc区为骨架的融合蛋白二聚体及其应用 | |
| JP2022521937A5 (https=) | ||
| JP2017504577A5 (https=) | ||
| Asano et al. | Domain order of a bispecific diabody dramatically enhances its antitumor activity beyond structural format conversion: the case of the hEx3 diabody | |
| JP2016527314A5 (https=) | ||
| AU2017361846A1 (en) | T cell recruiting polypeptides capable of binding CD123 and TCR alpha/beta | |
| JP2017504578A5 (https=) | ||
| JP2024511465A5 (https=) | ||
| CN105229036A (zh) | 在疏水性相互作用位点内引入了静电相互作用的蛋白及其制备方法 | |
| JP2023553694A5 (https=) | ||
| JP2019505565A5 (https=) |